Phage therapy

F. Laurent, PU-PH/ C. Kolenda, PHU/F. Laumay, MCU

To address the challenge of treatment failure, we combined innovative strategies to isolate, characterise, select, produce, purify, and formulate lytic phages for clinical use.

The PPR-AMR PHAG-ONE Project and the RHU THERAPhage project focused on:

i) A comprehensive phenotypic and molecular understanding of phage activity to improve therapeutic efficacy and adapt phages to overcome bacterial resistance mechanisms,

 ii) Deciphering the dynamics between phages and bacterial cells to better target therapeutic regimens,

 iii) Investigating the molecular and cellular mechanisms underlying bacterial resistance to phages to inform strategies that improve the robustness of phage therapy,

 iv) Development of in vivo models (Galleria, zebrafish, rabbit) to enable high-throughput screening of phage activity and preclinical evaluation of therapeutic efficacy against Staphylococcus species.